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OBJECTIVE: Dengue infection is a major public health
problem in tropical countries, home to 2.5 billion
persons. Every year, tens of million people get infected
and many of them develop acute disease with temporary
disability. While improved treatment has lowered the case
fatality rate, the high incidence of the disease keeps the
absolute burden of death high. Southeast Asia (SEA) is a
particularly vulnerable region, where most of the dengue
cases occur. Environmental control intervention to con-
trol mosquito breeding is expensive, erratic, and very 
difﬁcult to sustain. A dengue vaccine, currently in steps
of development, appears to be a promising public health
intervention to dengue control. We conducted a cost-
effectiveness analysis (CEA) to evaluate the net health
beneﬁts and costs of administering dengue vaccination to
annual birth cohorts in SEA.
METHOD: We updated and improved a CEA model 
published in 1993 by two of the authors. The model was
validated to the epidemiological and economic data for
the SEA region, where 529 million people live. The target
of the vaccination was the cohort of 12 million children
born in SEA each year. We assumed 2 doses of vaccine
would be required to provide lifetime protection with
95% efﬁcacy. We also assumed a dose cost of $5. We
compared the impact of vaccination against the current
situation and against a comprehensive vector control
program. We used a societal perspective and the cohort
lifetime as the timeframe and discounted Disability
Adjusted Life Years (DALYS) and economic outcomes at
an annual real rate of 3%.
RESULTS: Providing vaccination to a birth cohort in SEA
would cost $389 per QALY saved. A comprehensive envi-
ronmental control program was less favorable ($5,000
per QALY gained).
CONCLUSIONS: Dengue vaccination appears to be a
very cost-effective strategy to control dengue. This ﬁnding
supports the need to accelerate the development and 
commercialization of an efﬁcacious dengue vaccine.
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OBJECTIVES: To determine the impact of respiratory
syncytial virus (RSV) infection on healthcare resource use
and costs in the United States.
METHODS: The study retrospectively analyzed data
from three separate, federally funded databases that 
comprise nationally representative samples of 1) hospital
inpatient stays (1993–1997), 2) physician ofﬁce visits
(1997–1999), and 3) visits to hospital outpatient depart-
ments and emergency rooms (1997–1999). Each record
in these databases contained information on patient diag-
noses, tests and procedures performed during visit, and
prescribed drugs (not available on inpatient records).
Identiﬁcation of RSV-related medical encounters was
based on the occurrence of RSV-speciﬁc ICD-9-CM diag-
nosis codes (079.6, 466.11, 480.1) or the assumption that
20% of all otitis media visits (ICD-9-CM 380.0–380.4,
382.x) were due to RSV.
RESULTS: In 1997, there were approximately 87,400
hospitalizations, 5 million ofﬁce visits, 749,000 emer-
gency room visits and 494,000 hospital outpatient visits
attributable to RSV. Nearly 99% of RSV-related hospi-
talizations occurred in children <5 years old. Average
length of hospital stay for RSV-related bronchiolitis 
and pneumonia was 3.4 and 4.4 days, respectively. The
estimated average charges for RSV-related utilization in
1997 were as follows: $8,839 per hospitalization, $114
per ofﬁce visit, $473 per emergency room visit and $162
per hospital outpatient visit. Total annual costs for all
RSV-related hospitalizations ($770 million) and physician
visits ($1 billion) were estimated at $1.77 billion. Otitis
media was the major cost driver for physician visits. Both
RSV-related hospitalizations and total costs increased
over the period of 1993–1997.
CONCLUSIONS: Treatment of RSV-related illness 
represents a signiﬁcant health care burden in the US.
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OBJECTIVES: Despite widespread childhood immuniza-
tion, there is a resurgence of pertussis infections and resul-
tant clinical sequelae as adults infect children who are 
too young to be fully vaccinated or whose immunity is
waning. A reduced antigen dTpa booster pertussis vaccine
